Arcus Biosciences (RCUS) COO receives 31,000 RSUs and 126,000 options

Rhea-AI Filing Summary

Arcus Biosciences Chief Operating Officer receives new equity awards. On January 23, 2026, COO Jennifer Jarrett was granted 31,000 shares of common stock in the form of restricted stock units, which vest in four equal annual installments beginning on December 15, 2026, as long as she continues serving the company. She also received a stock option covering 126,000 shares of common stock at an exercise price of $22.13 per share. This option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to her continued service. Following these grants, she directly holds 224,024 shares of common stock, including unvested RSUs, and 126,000 stock options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jarrett Jennifer

(Last) (First) (Middle)

C/O ARCUS BIOSCIENCES, INC.

3928 POINT EDEN WAY

(Street)

HAYWARD CA 94545

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arcus Biosciences, Inc. [ RCUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/23/2026		A		31,000(1)	A	$0	224,024(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$22.13	01/23/2026		A		126,000		(3)	01/22/2036	Common Stock	126,000	$0	126,000	D

Explanation of Responses:

1. Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company.

2. Includes the unvested portion of the Reporting Person's RSU grants.

3. The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.

Remarks:

	/s/ Carolyn Tang, Attorney-in-Fact	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Arcus Biosciences (RCUS) report for Jennifer Jarrett?

Arcus Biosciences reported that Chief Operating Officer Jennifer Jarrett received equity awards on January 23, 2026, consisting of restricted stock units and stock options.

How many restricted stock units did the Arcus Biosciences (RCUS) COO receive?

The COO received 31,000 restricted stock units (RSUs), representing shares of Arcus Biosciences common stock that vest over time.

What are the vesting terms for the 31,000 RSUs at Arcus Biosciences (RCUS)?

The 31,000 RSUs vest in four equal annual installments beginning on December 15, 2026, conditioned on the COO’s continued service to the company.

What stock options were granted to the Arcus Biosciences (RCUS) COO in this Form 4?

The filing shows a grant of a stock option for 126,000 shares of Arcus Biosciences common stock with an exercise price of $22.13 per share.

When do the new stock options for Arcus Biosciences (RCUS) COO become exercisable?

The 126,000-share option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the COO’s continued service.

How many Arcus Biosciences (RCUS) shares does the COO own after these grants?

After the reported transactions, the COO directly beneficially owns 224,024 shares of common stock, which includes the unvested portion of her RSU grants, and 126,000 stock options.

Are the reported Arcus Biosciences (RCUS) equity awards to the COO direct or indirect holdings?

The Form 4 indicates that both the 224,024 common shares and the 126,000 stock options are held with direct ownership by the COO.